Discover MabDesign
MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.
Access our network
Join the MabDesign network to take advantage of all the advantages and opportunities offered.
Develop your skills
Consult and register for our next training courses in order to acquire new expertise.
Explore our business services
The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.
Upcoming events
Add your title here
09
Apr.
April 9-11, 2024
Partner Event
22
Apr.
April 22-23, 2024
Partner Event
29
Apr.
April 29-30, 2024
Partner Event
16
May.
16 & 17 mai 2024
Other Events
17
May.
17 May, 2024
Mabdesign Event
22
May.
May 22, 2024
Mabdesign Event
Our News
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).
Advanced therapy medicinal products: from the lab to the patient's bed
Advanced therapy medicinal products (ATMPs) explore new therapeutic approaches based on genome modification, manipulation of patient or healthy donor cells and other innovative methods, representing a major transition from traditional medicine to more personalized and targeted medicine.